FTLF FitLife Brands, Inc.

NASDAQ
$6.20

FitLife Brands Misses as Irwin Acquisition Masks Shrinking Legacy Business and Stalled Deleveraging

FitLife Brands missed third-quarter expectations on both lines, and the shortfall is more revealing than the year-over-year growth figures suggest. Earnings Whispers puts adjusted earnings at $0.19 per share, 24.0% below the $0.25 consensus and flat (0.0%) from a year ago. Revenue of $25.62 million rose 9.1% year over year but missed the $27.1 million consensus by 5.5%. That growth came almost entirely from owning Irwin Naturals for a full quarter instead of the eight weeks it contributed in the prior-year period. The central tension is that a company bought for scale is producing a flat run-rate with softer profits, while its legacy franchise keeps shrinking.

The quality of the quarter deserves scrutiny. GAAP net income rose 71% to $1.6 million, and diluted GAAP EPS reached $0.16 versus $0.09. That improvement came mainly from the absence of last year's $0.8 million in merger costs and a lower tax rate, not from better operations. Adjusted EBITDA fell 13% to $3.3 million from $3.8 million and declined sequentially from $3.7 million in Q2. Total revenue slipped 3.4% from Q2's $26.5 million, reversing the prior quarter's sequential gain. Legacy FitLife revenue fell 24% year over year to $12.6 million:

  • Wholesale dropped 34%, largely because of GNC.
  • Online declined 18%, driven by MRC.
  • The wholesale decline has steepened each quarter this year, from -28% to -31% to -34%.

The call did preserve some genuine operating progress. Consolidated gross margin improved to 37.7% from 37.0% in Q2, and Legacy FitLife gross margin climbed to 41.6% from 39.3% a year earlier. Online revenue grew 15% to $11.8 million, or 46% of sales. Irwin's online business reached $3.6 million, 28% of the brand's revenue versus 20% in Q1, with an Amazon run-rate above $12 million. MusclePharm hit all-time-high online sales, and management said its margins are now above 25% versus roughly 20% previously. The problem is that these gains are being offset elsewhere:

  • Irwin's total revenue fell to $13.0 million from $14.1 million.
  • Irwin wholesale dropped to $9.4 million from $10.7 million as specialty-retail weakness spread into its health food store channel.
  • The call raised the possibility that Amazon growth is cannibalizing that channel.

Management's response is cost discipline rather than growth. A restructuring completed in Q3 cost about $0.3 million and is expected to cut annual operating expense by roughly $1.2 million starting in Q4, with additional lease savings noted on the call. Other levers include:

  • Forward purchases that lock in most fish oil needs for about a year.
  • Whey purchased below spot prices.
  • Planned packaging and Amazon listing changes intended to lower fulfillment costs.

The risks are concrete, however. The call indicated locked-in whey supply is nearly used up while spot prices sit around $9-10 per pound, and fish oil faces a supply shortage. GNC, roughly a tenth of revenue, is declining 15-25%. Management also noted that Q4 is seasonally the weakest quarter.

The balance sheet also moved the wrong way. Net debt rose to $38.6 million from $37.0 million at the end of Q2, with cash of just $0.7 million, ending a stretch of steady quarterly paydown. Management attributed the increase entirely to temporary working-capital swings, including the commodity prepayments, and said it expects debt reduction to resume. That is plausible, but it remains an expectation rather than a result. There is still no formal guidance. Trailing-twelve-month revenue of $103.4 million and adjusted EBITDA of $13.7 million remain well short of the roughly $120 million revenue and $20-25 million EBITDA framing discussed around the acquisition.

Investors had already turned skeptical before the report, and the setup has deteriorated further. Earnings Whispers sentiment fell from -0.12 to -0.39, a meaningful shift deeper into negative territory. Shares at $6.83 are down 33.6% since the open following the August report and sit about 36.5% below the 200-day moving average of $10.76. Price and AVWAP trend readings remain negative. The market has been pricing in exactly the stagnation this quarter displayed, and the miss gives bears more ammunition than the margin gains give bulls.

The bottom line is that FitLife delivered a miss on both lines, with flat adjusted earnings, falling EBITDA, accelerating legacy wholesale erosion, and a pause in deleveraging. These outweigh real improvements in gross margin, online mix, and MusclePharm. The restructuring savings and commodity hedges could stabilize profitability, but without guidance, with input costs rising, and with specialty retail still deteriorating, FitLife has to show that the business can stop shrinking at its core before the acquisition thesis regains credibility.

← Back to FTLF news

Read our preview of this report →